ES2635318T3 - Moduladores P2X7 - Google Patents

Moduladores P2X7 Download PDF

Info

Publication number
ES2635318T3
ES2635318T3 ES14718857T ES14718857T ES2635318T3 ES 2635318 T3 ES2635318 T3 ES 2635318T3 ES 14718857 T ES14718857 T ES 14718857T ES 14718857 T ES14718857 T ES 14718857T ES 2635318 T3 ES2635318 T3 ES 2635318T3
Authority
ES
Spain
Prior art keywords
alkyl
independently selected
perhaloalkyl
halo
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14718857T
Other languages
English (en)
Other versions
ES2635318T7 (es
Inventor
Manuel Jesus Alcazar Vaca
Brett D. Allison
Jose Ignacio Andres Gil
Christa C. Chrovian
Heather R. COATE
Meri De Angelis
Xiaohu Deng
Curt A. Dvorak
Christine F. GELIN
Michael A. Letavic
Jimmy T. Liang
Neelakandha S. Mani
Jason C. Rech
Brad M. Savall
Akinola Soyode-Johnson
Brice M. STENNE
Devin M. Swanson
Jessica L. WALL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of ES2635318T3 publication Critical patent/ES2635318T3/es
Application granted granted Critical
Publication of ES2635318T7 publication Critical patent/ES2635318T7/es
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)

Abstract

Un compuesto de Fórmula (I): **Fórmula** en la que R1 es (a)fenilo, opcionalmente sustituido con cero a cuatro grupos seleccionados independientemente del grupo que consiste en halo, C1-C4 alquilo, alcoxi, perhaloalquilo y perhaloalcoxi; o (b) heteroarilo, selecciona independientemente del grupo que consiste en: **Fórmula** en la que Rk se selecciona independientemente del grupo que consiste en H, halo, C1-C3 alquilo, hidroxilo, perhaloalquilo y alcoxi; Rj se selecciona independientemente de H o C1-C3 alquilo en el que C1-C3 alquilo está opcionalmente sustituido con de uno a tres sustituyentes halo, un sustituyente OH o un sustituyente alcoxi; y n es un número entero 0-3; X es N o CR2; R2 es H, perhaloalquilo o C1-C3 alquilo inferior; R3 es H, perhaloalquilo, C1-C4 alquilo, alkalkoxy, CH2 Ri, -C(O)Re o fenilo, en el que dicho fenilo está opcionalmente sustituido con cero a dos grupos independientemente seleccionados del grupo que consiste de halo, C1-C3 alquilo **Fórmula** alcoxi, perhaloalquilo y perhaloalcoxi; Ri es OH, NC3 H6, N (C1-C3 alquilo)2 o halo; Re es OH, OC1-C3 alquilo, N (C1-C3 alquilo)2 , o NC3 H6; R4 y R5 son independientemente H o C1-C3 alquilo; R8 es fenilo o piridilo, opcionalmente sustituido con cero a cuatro Rm sustituyentes en los que Rm se selecciona independientemente del grupo que consiste en halo, C1-C3 alquilo, hidroxi, alcoxi, perhaloalquilo y perhaloalcoxi; o R8 se selecciona independientemente del grupo que consiste **Fórmula** y sales farmacéuticamente aceptables de compuestos de Fórmula (I).
ES14718857T 2013-03-14 2014-03-14 Moduladores P2X7 Active ES2635318T7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361786260P 2013-03-14 2013-03-14
PCT/US2014/027522 WO2014152604A1 (en) 2013-03-14 2014-03-14 P2x7 modulators

Publications (2)

Publication Number Publication Date
ES2635318T3 true ES2635318T3 (es) 2017-10-03
ES2635318T7 ES2635318T7 (es) 2018-09-11

Family

ID=50543353

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17172541T Active ES2704024T3 (es) 2013-03-14 2014-03-14 Moduladores P2X7
ES14718857T Active ES2635318T7 (es) 2013-03-14 2014-03-14 Moduladores P2X7

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES17172541T Active ES2704024T3 (es) 2013-03-14 2014-03-14 Moduladores P2X7

Country Status (33)

Country Link
US (8) US10112937B2 (es)
EP (3) EP3495365A1 (es)
JP (1) JP6293861B2 (es)
KR (5) KR102516711B1 (es)
CN (2) CN110003200B (es)
AR (2) AR095530A1 (es)
AU (5) AU2014239291B2 (es)
BR (1) BR112015023142B1 (es)
CA (1) CA2906085C (es)
CL (3) CL2015002655A1 (es)
CY (1) CY1119110T1 (es)
DK (2) DK3239151T3 (es)
EA (1) EA028816B1 (es)
ES (2) ES2704024T3 (es)
HR (1) HRP20171168T4 (es)
HU (1) HUE032877T2 (es)
IL (1) IL240880B (es)
JO (1) JO3773B1 (es)
LT (1) LT2970267T (es)
ME (1) ME02802B (es)
MX (2) MX364796B (es)
PH (1) PH12015501930A1 (es)
PL (1) PL2970267T6 (es)
PT (2) PT2970267T (es)
RS (1) RS56315B2 (es)
SG (2) SG11201507259UA (es)
SI (1) SI2970267T1 (es)
SM (1) SMT201700352T1 (es)
TW (2) TWI644671B (es)
UA (1) UA116467C2 (es)
UY (3) UY35469A (es)
WO (1) WO2014152604A1 (es)
ZA (1) ZA201507627B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節物質
GEP201706780B (en) 2013-03-14 2017-11-27 Boehringer Ingelheim Int Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015172196A1 (en) * 2014-05-13 2015-11-19 Monash University Heterocyclic compounds and use of same
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
EA201790600A1 (ru) 2014-09-12 2017-07-31 Янссен Фармацевтика Нв Модулирующие p2x7 n-ацил-триазолопиразины
JP6358639B2 (ja) 2015-04-24 2018-07-18 塩野義製薬株式会社 ６員複素環誘導体およびそれらを含有する医薬組成物
ES2757052T3 (es) * 2015-07-31 2020-04-28 Merck Patent Gmbh Derivados heterocíclicos bicíclicos
MX393004B (es) 2016-10-17 2025-03-24 Shionogi & Co Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene.
EP3548613B1 (en) 2016-12-02 2021-01-27 Fraunhofer Gesellschaft zur Förderung der Angewand Bacterial glutaminyl cyclase inhibitors and use thereof in the treatment of periodontitis
PT3609868T (pt) 2017-03-13 2023-12-18 Raqualia Pharma Inc Derivados de tetra-hidroquinolina como antagonistas do recetor p2x7
WO2019099509A1 (en) * 2017-11-14 2019-05-23 Second Genome, Inc. Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
EP3746429B1 (en) * 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
EP3837263B1 (en) 2018-08-13 2024-07-03 F. Hoffmann-La Roche AG New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020065614A1 (en) * 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CN113164459B (zh) * 2018-09-28 2024-09-03 詹森药业有限公司 单酰基甘油脂肪酶调节剂
EP3883936B1 (en) 2018-11-22 2023-07-12 F. Hoffmann-La Roche AG New heterocyclic compounds
CN109400605A (zh) * 2018-11-27 2019-03-01 复旦大学附属中山医院 一种p2x7受体显像剂及其制备方法
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
ES3037365T3 (en) * 2019-09-30 2025-10-01 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
CN114945561A (zh) 2020-01-13 2022-08-26 阿普塔生物治疗公司 新吡唑衍生物
BR112022019077A2 (pt) * 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
CN115894452B (zh) * 2021-08-18 2024-04-09 四川大学 一种p2x7受体抑制剂
WO2025091145A1 (zh) * 2023-10-30 2025-05-08 复旦大学 糖尿病肾病诊断药物及应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
AU2003244649A1 (en) 2002-07-25 2004-02-23 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003244632A1 (en) 2002-07-25 2004-02-25 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
FR2857363B1 (fr) 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
WO2006023750A2 (en) 2004-08-23 2006-03-02 Merck & Co., Inc. Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1844003A4 (en) 2005-01-27 2010-09-22 Astrazeneca Ab NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
KR20100023040A (ko) 2007-06-21 2010-03-03 쉐링 코포레이션 폴리사이클릭 구아닌 유도체 및 이의 용도
BRPI0812594A2 (pt) * 2007-08-10 2015-06-23 Lundbeck & Co As H Composto ou sal ou hidrato do mesmo, composição farmacêutica, métodos para modulação da atividade de um receptor p2x7, para tratamento de uma condição responsiva á modulação do receptor p2x7 em um paciente, para inibição de morte de células gangliônicas retinais em um paciente, para determinação da presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal ou hidrato do mesmo.
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
CA2722035C (en) 2008-04-22 2016-10-11 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted p2x7 antagonists
WO2010060854A1 (en) * 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
JP5654001B2 (ja) * 2009-04-29 2015-01-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐ２Ｘ７調節因子としての５，６，７，８−テトラヒドロ［１，２，４］トリアゾロ［４，３−ａ］ピラジン誘導体
GB0907515D0 (en) * 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
MX342161B (es) 2010-04-02 2016-09-19 Euroscreen Sa Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
US20110252717A1 (en) 2010-04-16 2011-10-20 Graf Fernandez Rodrigo Foldable structures for a construction
EP2619204A4 (en) 2010-09-21 2014-08-27 Merck Sharp & Dohme TRIAZOLOPYRAZINONE AS P2X7 RECEPTOR ANTAGONISTS
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
US9273947B2 (en) 2012-02-07 2016-03-01 Lg Innotek Co., Ltd. Sensing magnet apparatus for motor
JP5205547B1 (ja) 2012-04-20 2013-06-05 株式会社ノイズ研究所 放射信号可視化装置
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
AU2013331380B2 (en) 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
TWI606045B (zh) 2012-10-16 2017-11-21 健生藥品公司 ＲＯＲγｔ之亞甲基聯結的喹啉基調節劑
AU2013337824B2 (en) 2012-11-01 2018-03-08 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
KR102212923B1 (ko) 2012-12-21 2021-02-04 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
KR20150100814A (ko) 2012-12-21 2015-09-02 콴티셀 파마슈티컬스, 인크. 히스톤 데메틸라제 억제제
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
NZ710640A (en) 2013-03-06 2019-03-29 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
RU2667509C2 (ru) 2013-03-14 2018-09-21 Ньюлинк Джинетикс Корпорейшин Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節物質
HUE039473T2 (hu) 2013-03-14 2019-01-28 Curadev Pharma Private Ltd Kinurenin útvonal inhibitorok
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
GEP201706780B (en) 2013-03-14 2017-11-27 Boehringer Ingelheim Int Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
WO2014140076A1 (en) 2013-03-14 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
CA2907814C (en) 2013-03-29 2021-07-13 Euroscreen Sa Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
EA201790600A1 (ru) 2014-09-12 2017-07-31 Янссен Фармацевтика Нв Модулирующие p2x7 n-ацил-триазолопиразины
CN113164459B (zh) 2018-09-28 2024-09-03 詹森药业有限公司 单酰基甘油脂肪酶调节剂
ES3037365T3 (en) 2019-09-30 2025-10-01 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands

Also Published As

Publication number Publication date
KR20220044376A (ko) 2022-04-07
JP6293861B2 (ja) 2018-03-14
IL240880B (en) 2019-05-30
PH12015501930A1 (en) 2016-01-04
KR20150127723A (ko) 2015-11-17
EP3239151B1 (en) 2018-11-07
PL2970267T6 (pl) 2018-11-30
NZ711699A (en) 2020-10-30
US20240116930A1 (en) 2024-04-11
EP3239151A1 (en) 2017-11-01
UY35469A (es) 2014-09-30
EP3495365A1 (en) 2019-06-12
TW201446762A (zh) 2014-12-16
CN110003200A (zh) 2019-07-12
JO3773B1 (ar) 2021-01-31
AU2014239291B2 (en) 2017-06-15
MX364796B (es) 2019-05-07
EP2970267A1 (en) 2016-01-20
DK3239151T3 (en) 2019-01-21
AR123048A2 (es) 2022-10-26
KR20210132743A (ko) 2021-11-04
CN105209464B (zh) 2019-01-01
AU2021236451A1 (en) 2021-10-14
CL2015002655A1 (es) 2016-03-04
AU2019203186B2 (en) 2021-06-24
US10112937B2 (en) 2018-10-30
KR20250004140A (ko) 2025-01-07
SG10201700889PA (en) 2017-03-30
CL2017002609A1 (es) 2018-03-16
TWI599567B (zh) 2017-09-21
UY39887A (es) 2023-06-15
TW201740940A (zh) 2017-12-01
KR102516711B1 (ko) 2023-03-30
CN105209464A (zh) 2015-12-30
RS56315B2 (sr) 2018-08-31
US20200325138A1 (en) 2020-10-15
JP2016515135A (ja) 2016-05-26
LT2970267T (lt) 2017-07-10
UY39888A (es) 2022-09-30
KR20230049754A (ko) 2023-04-13
RS56315B1 (sr) 2017-12-29
PT2970267T (pt) 2017-08-25
US20220213095A1 (en) 2022-07-07
UA116467C2 (uk) 2018-03-26
DK2970267T3 (en) 2017-07-24
CA2906085A1 (en) 2014-09-25
MX2015012095A (es) 2016-05-10
US9464084B2 (en) 2016-10-11
BR112015023142A8 (pt) 2019-12-03
PT3239151T (pt) 2019-01-28
HRP20171168T4 (hr) 2018-09-21
EP2970267B1 (en) 2017-05-24
US20140275015A1 (en) 2014-09-18
BR112015023142B1 (pt) 2023-05-02
CL2017002610A1 (es) 2018-03-16
TWI644671B (zh) 2018-12-21
US10703749B2 (en) 2020-07-07
HUE032877T2 (hu) 2017-11-28
AU2019203186A1 (en) 2019-05-30
SG11201507259UA (en) 2015-10-29
AU2017206153B2 (en) 2019-02-14
US20150322062A1 (en) 2015-11-12
ME02802B (me) 2018-01-20
AR095530A1 (es) 2015-10-21
MX2022011795A (es) 2022-10-10
IL240880A0 (en) 2015-10-29
EA201591748A1 (ru) 2016-02-29
EP2970267B3 (en) 2018-05-30
HK1218541A1 (en) 2017-02-24
PL2970267T3 (pl) 2017-11-30
BR112015023142A2 (pt) 2017-07-18
AU2017206153A1 (en) 2017-08-17
SMT201700352T1 (it) 2017-09-07
AU2014239291A1 (en) 2015-09-17
AU2024201709A1 (en) 2024-04-04
CY1119110T1 (el) 2018-02-14
US20160376271A1 (en) 2016-12-29
ES2635318T7 (es) 2018-09-11
AU2021236451B2 (en) 2024-02-01
ES2704024T3 (es) 2019-03-13
WO2014152604A1 (en) 2014-09-25
US11820770B2 (en) 2023-11-21
CN110003200B (zh) 2021-11-26
US20190092770A1 (en) 2019-03-28
US9066946B2 (en) 2015-06-30
CA2906085C (en) 2023-01-03
EA028816B1 (ru) 2018-01-31
US12247027B2 (en) 2025-03-11
ZA201507627B (en) 2023-11-29
SI2970267T1 (sl) 2017-08-31
US20160039809A1 (en) 2016-02-11
DK2970267T6 (en) 2018-09-03
KR102500076B1 (ko) 2023-02-14
KR102319857B1 (ko) 2021-11-01
US10150765B2 (en) 2018-12-11
US11225478B2 (en) 2022-01-18
HRP20171168T1 (hr) 2017-10-06

Similar Documents

Publication Publication Date Title
ES2635318T3 (es) Moduladores P2X7
MX2015012815A (es) Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores de bromodominio.
CO2018012171A2 (es) Piridinas sustituidas con heteroarilo y métodos de uso
NI201500130A (es) 2-azabiciclo sustituidos y su uso como moduladores del receptor de orexina
PE20181145A1 (es) Compuestos de piridina
ES2631611T3 (es) Amidas de piperidina de Pirano-Espirociclico como moduladores de canales iónicos
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
PE20160961A1 (es) Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de respuestas de citocinas heterodimericas interleucina 12 y 23 (il-12 e il-23) y/o interferon alfa (ifnalfa)
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
JO3509B1 (ar) معدلات p2x7
AR092742A1 (es) Piridinonas antifibroticas
CR20160296A (es) Benzamidas sustituidas y métodos para usarlas
CU20140105A7 (es) Composición para el control de plagas que incluye un derivado de iminopiridina novedoso
AR093515A1 (es) Triazolopirazinas
ES2587284T3 (es) 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9
MX387483B (es) Preparación farmacéutica.
BR112019007980A2 (pt) método para produzir 3-alquilsulfanil-2-cloro-n-(1-alquil-1h-tetrazol-5-il)-4-trifluorometil-benzamidas
MX2018003276A (es) Compuesto farmaceutico.
CR20180298A (es) Nuevos derivados de fenilo
CR20160082A (es) Nuevo derivado de triazina
AU2015309863A8 (en) Azaindole derivative having AMPK-activating effect
MY185971A (en) Pyranodipyridine compound
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
MX2018001214A (es) Mezcla aditiva.